Literature DB >> 23522062

IL28B genotype and the expression of ISGs in normal liver.

Zoe Raglow1, Carly Thoma-Perry, Richard Gilroy, Yu-Jui Y Wan.   

Abstract

BACKGROUND & AIMS: Both polymorphisms in the IL28B gene locus and ISG expression levels are associated with the outcome of hepatitis C virus (HCV) infection. The two are also interrelated, although the mechanism is unknown. Favourable CC genotype at rs12979860 expresses lower baseline ISG levels and responds better to treatment than unfavourable CT and TT genotypes. Little is known about this relationship in normal, uninfected liver. This study sought to explore this relationship.
METHODS: Normal human liver specimens (64) and HCV positive human liver specimens (95) were genotyped for IL28B rs12979860 C > T. mRNA levels of ISGs and other relevant genes were studied by qPCR.
RESULTS: Most studied ISGs had significantly different expression by IL28B genotype in normal liver. CC genotype expressed the highest levels, CT intermediate and TT the lowest. This is opposite to the pattern seen in HCV patients. Principal component analysis of IL28B genotype and ISG expression further revealed a distinct set of genes correlated with the C allele (ISG15, HTATIP2, LGALS3BP, IRF2 and BCL2) and T allele (IFNα, β, γ, λ3 and CD80).
CONCLUSION: A subset of ISGs was found to be differentially expressed in normal liver by IL28B genotype. This suggests a relationship between IL28B genotype and gene expression before HCV infection.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL28B; gene expression; hepatitis C virus; interferon-stimulated genes

Mesh:

Substances:

Year:  2013        PMID: 23522062      PMCID: PMC7231429          DOI: 10.1111/liv.12148

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  39 in total

1.  IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.

Authors:  Salvatore Petta; Stefania Grimaudo; Calogero Cammà; Daniela Cabibi; Vito Di Marco; Giusalba Licata; Rosaria Maria Pipitone; Antonio Craxì
Journal:  J Hepatol       Date:  2012-02-05       Impact factor: 25.083

2.  Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C.

Authors:  Eleanor L Ramos
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

3.  bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection.

Authors:  E Zuckerman; T Zuckerman; D Sahar; S Streichman; D Attias; E Sabo; D Yeshurun; J Rowe
Journal:  Br J Haematol       Date:  2001-02       Impact factor: 6.998

4.  Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection.

Authors:  Julia M Sugalski; Benigno Rodriguez; Susan Moir; Donald D Anthony
Journal:  J Immunol       Date:  2010-07-23       Impact factor: 5.422

5.  Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Authors:  Christoph Sarrazin; Simone Susser; Alexandra Doehring; Christian Markus Lange; Tobias Müller; Christina Schlecker; Eva Herrmann; Jörn Lötsch; Thomas Berg
Journal:  J Hepatol       Date:  2010-09-22       Impact factor: 25.083

6.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

Authors:  Michael T Dill; Francois H T Duong; Julia E Vogt; Stéphanie Bibert; Pierre-Yves Bochud; Luigi Terracciano; Andreas Papassotiropoulos; Volker Roth; Markus H Heim
Journal:  Gastroenterology       Date:  2010-11-25       Impact factor: 22.682

7.  Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation.

Authors:  A Masumi; H Fukazawa; T Shimazu; M Yoshida; K Ozato; K Komuro; K Yamaguchi
Journal:  Oncogene       Date:  2006-04-03       Impact factor: 9.867

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients.

Authors:  Palma A Iacovazzi; Raffaele Cozzolongo; Elsa Lanzillotta; Stefania Frisullo; Vito Guerra; Mario Correale
Journal:  Immunopharmacol Immunotoxicol       Date:  2008       Impact factor: 2.730

10.  Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.

Authors:  P S Vaughan; F Aziz; A J van Wijnen; S Wu; H Harada; T Taniguchi; K J Soprano; J L Stein; G S Stein
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962

View more
  14 in total

Review 1.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

2.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

Review 3.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

Review 4.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Authors:  Rikke Olesen; Selena Vigano; Thomas A Rasmussen; Ole S Søgaard; Zhengyu Ouyang; Maria Buzon; Arman Bashirova; Mary Carrington; Sarah Palmer; Christel R Brinkmann; Xu G Yu; Lars Østergaard; Martin Tolstrup; Mathias Lichterfeld
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

Review 6.  Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.

Authors:  Ulrich Spengler; Hans Dieter Nischalke; Jacob Nattermann; Christian P Strassburg
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study.

Authors:  Heidar Sharafi; Seyed Moayed Alavian; Bita Behnava; Ali Pouryasin; Maryam Keshvari
Journal:  Hepat Mon       Date:  2014-10-01       Impact factor: 0.660

8.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Authors:  Mohammed Eslam; Ahmed M Hashem; Reynold Leung; Manuel Romero-Gomez; Thomas Berg; Gregory J Dore; Henry L K Chan; William L Irving; David Sheridan; Maria L Abate; Leon A Adams; Alessandra Mangia; Martin Weltman; Elisabetta Bugianesi; Ulrich Spengler; Olfat Shaker; Janett Fischer; Lindsay Mollison; Wendy Cheng; Elizabeth Powell; Jacob Nattermann; Stephen Riordan; Duncan McLeod; Nicola J Armstrong; Mark W Douglas; Christopher Liddle; David R Booth; Jacob George; Golo Ahlenstiel
Journal:  Nat Commun       Date:  2015-03-05       Impact factor: 14.919

9.  Interferon Lambda 3/4 (IFNλ3/4) rs12979860 Polymorphisms Is Not Associated With Susceptibility to Systemic Lupus Erythematosus, Although It Regulates OASL Expression in Patients With SLE.

Authors:  Yaneli Juárez-Vicuña; Julia Pérez-Ramos; Laura Adalid-Peralta; Fausto Sánchez; Laura Aline Martínez-Martínez; María Del Carmen Ortiz-Segura; Edgar Pichardo-Ontiveros; Adrián Hernández-Díazcouder; Luis M Amezcua-Guerra; Julian Ramírez-Bello; Fausto Sánchez-Muñoz
Journal:  Front Genet       Date:  2021-06-02       Impact factor: 4.599

10.  Interferon-λ Genetic Variations and Hepatitis C: Yet to be Discovered.

Authors:  Maryam Keshvari; Heidar Sharafi
Journal:  Hepat Mon       Date:  2014-05-10       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.